PYMNTS.com January 19, 2025
23andMe is reportedly considering the sale of Lemonaid Health, its telehealth operation.
The consumer genetic testing kit company acquired Lemonaid in 2021 for $400 million and is now weighing a sale, per a Friday (Jan. 17) Business Insider report that cited sources familiar with the matter.
PYMNTS has contacted 23andMe for comment but has not yet gotten a reply.
The news comes months after 23andMe announced it was cutting more than 200 jobs — or around 40% of its staff — as part of a larger restructuring.
The company’s stock has plunged since a 2023 data breach that exposed the private information of around 7 million customers. 23andMe revealed the breach in October 2023, around six months after it began,...
Today's Sponsors
Today's Sponsor